Your browser doesn't support javascript.
loading
Host, Viral, and Environmental Transcriptome Profiles of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Daniel J Butler; Christopher Mozsary; Cem Meydan; David C Danko; Jonathan Foox; Joel Rosiene; Alon Shaiber; Ebrahim Afshinnekoo; Matthew MacKay; Fritz J Sedlazeck; Nikolay A Ivanov; Maria A Sierra; Diana Pohle; Michael Zietz; Undina Gisladottir; Vijendra Ramlall; Craig D Westover; Krista Ryon; Benjamin Young; Chandrima Bhattacharya; Phyllis Ruggiero; Bradley W Langhorst; Nathan A Tanner; Justyna Gawrys; Dmitry Meleshko; Dong Xu; Peter A D Steel; Amos J Shemesh; Jenny Xiang; Jean Thierry-Mieg; Danielle Thierry-Mieg; Robert E Schwartz; Angelika Iftner; Daniela Bezdan; John Sipley; Lin Cong; Arryn Craney; Priya Velu; Ari Melnick; Iman Hajirasouliha; Stacy M Horner; Thomas Iftner; Mirella Salvatore; Massimo Loda; Lars F Westblade; Shawn Levy; Melissa Cushing; Shixiu Wu; Nicholas P Tatonetti; Marcin Imielinski; Hanna Rennert; Christopher Mason.
Affiliation
  • Daniel J Butler; Weill Cornell Medicine
  • Christopher Mozsary; Weill Cornell Medicine
  • Cem Meydan; Weill Cornell Medicine
  • David C Danko; Weill Cornell Medicine
  • Jonathan Foox; Weill Cornell Medicine
  • Joel Rosiene; Weill Cornell Medicine
  • Alon Shaiber; Weill Cornell Medicine
  • Ebrahim Afshinnekoo; Weill Cornell Medicine
  • Matthew MacKay; Weill Cornell Medicine
  • Fritz J Sedlazeck; Baylor College of Medicine
  • Nikolay A Ivanov; Weill Cornell Medicine
  • Maria A Sierra; Weill Cornell Medicine
  • Diana Pohle; University Hospital Tuebingen
  • Michael Zietz; Columbia University
  • Undina Gisladottir; Columbia University
  • Vijendra Ramlall; Columbia University
  • Craig D Westover; Weill Cornell Medicine
  • Krista Ryon; Weill Cornell Medicine
  • Benjamin Young; Weill Cornell Medicine
  • Chandrima Bhattacharya; Weill Cornell Medicine
  • Phyllis Ruggiero; New York Presbyterian Hospital
  • Bradley W Langhorst; New England Biolabs
  • Nathan A Tanner; New England Biolabs
  • Justyna Gawrys; New York Presbyterian Hospital
  • Dmitry Meleshko; Weill Cornell Medicine
  • Dong Xu; Weill Cornell Medicine
  • Peter A D Steel; Weill Cornell Medicine
  • Amos J Shemesh; Weill Cornell Medicine
  • Jenny Xiang; Weill Cornell Medicine
  • Jean Thierry-Mieg; NIH
  • Danielle Thierry-Mieg; NIH
  • Robert E Schwartz; Weill Cornell Medicine
  • Angelika Iftner; University Hospital Tuebingen
  • Daniela Bezdan; University Hospital Tuebingen
  • John Sipley; New York Presbyterian Hospital
  • Lin Cong; New York Presbyterian Hospital
  • Arryn Craney; Weill Cornell Medicine
  • Priya Velu; Weill Cornell Medicine
  • Ari Melnick; Weill Cornell Medicine
  • Iman Hajirasouliha; Weill Cornell Medicine
  • Stacy M Horner; Duke University Medical Center
  • Thomas Iftner; University Hospital Tubingen
  • Mirella Salvatore; Weill Cornell Medicine
  • Massimo Loda; Weill Cornell Medicine
  • Lars F Westblade; Weill Cornell Medicine
  • Shawn Levy; HudsonAlpha Institute for Biotechnology
  • Melissa Cushing; Weill Cornell Medicine
  • Shixiu Wu; Hangzhou Cancer Hospital
  • Nicholas P Tatonetti; Columbia University
  • Marcin Imielinski; Weill Cornell Medicine
  • Hanna Rennert; Weill Cornell Medicine
  • Christopher Mason; Weill Cornell Medicine
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-048066
ABSTRACT
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused thousands of deaths worldwide, including >18,000 in New York City (NYC) alone. The sudden emergence of this pandemic has highlighted a pressing clinical need for rapid, scalable diagnostics that can detect infection, interrogate strain evolution, and identify novel patient biomarkers. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs, plus a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, bacterial, and viral profiling. We applied both technologies across 857 SARS-CoV-2 clinical specimens and 86 NYC subway samples, providing a broad molecular portrait of the COVID-19 NYC outbreak. Our results define new features of SARS-CoV-2 evolution, nominate a novel, NYC-enriched viral subclade, reveal specific host responses in interferon, ACE, hematological, and olfaction pathways, and examine risks associated with use of ACE inhibitors and angiotensin receptor blockers. Together, these findings have immediate applications to SARS-CoV-2 diagnostics, public health, and new therapeutic targets.
License
cc_no
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Prognostic_studies Language: En Year: 2020 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Prognostic_studies Language: En Year: 2020 Document type: Preprint